Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality

Hao Li,Lei-Ke Zhang,Shu-Fen Li,Shao-Fei Zhang,Wei-Wei Wan,Yu-Lan Zhang,Qi-Lin Xin,Ke Dai,Yuan-Yuan Hu,Zhi-Bo Wang,Xiang-Tao Zhu,Yu-Jie Fang,Ning Cui,Pan-He Zhang,Chun Yuan,Qing-Bin Lu,Jie-Ying Bai,Fei Deng,Geng-Fu Xiao,Wei Liu,Ke Peng
DOI: https://doi.org/10.1038/s41422-019-0214-z
IF: 44.1
2019-08-23
Cell Research
Abstract:Severe fever with thrombocytopenia syndrome (SFTS), an emerging tick-borne infectious disease caused by a novel phlebovirus (SFTS virus, SFTSV), was listed among the top 10 priority infectious diseases by the World Health Organization due to its high fatality of 12%–50% and possibility of pandemic transmission. Currently, effective anti-SFTSV intervention remains unavailable. Here, by screening a library of FDA-approved drugs, we found that benidipine hydrochloride, a calcium channel blocker (CCB), inhibited SFTSV replication in vitro. Benidipine hydrochloride was revealed to inhibit virus infection through impairing virus internalization and genome replication. Further experiments showed that a broad panel of CCBs, including nifedipine, inhibited SFTSV infection. The anti-SFTSV effect of these two CCBs was further analyzed in a humanized mouse model in which CCB treatment resulted in reduced viral load and decreased fatality rate. Importantly, by performing a retrospective clinical investigation on a large cohort of 2087 SFTS patients, we revealed that nifedipine administration enhanced virus clearance, improved clinical recovery, and remarkably reduced the case fatality rate by >5-fold. These findings are highly valuable for developing potential host-oriented therapeutics for SFTS and other lethal acute viral infections known to be inhibited by CCBs in vitro.
cell biology
What problem does this paper attempt to address?